3D printing of modular ‘polypills’ for personalised therapy (Video Interview)

Interview with Beatriz Pereira, University of Central Lancashire, for JakajimaTV hosted by Pieter Hermans. Current healthcare follows an ‘one size fits all’ approach, and it is associated with high variations in treatment outcomes, due to the high interindividual variability.

Continue reading “3D printing of modular ‘polypills’ for personalised therapy (Video Interview)”

Custom 3D-printed organic implants project funded with CHF 12 million

organic

Researchers at the University of Basel have a vision: an individually configurable robot that will revolutionize surgical procedures and provide numerous benefits for patients. They have already taken the first steps in this direction. To further implement their vision, the Werner Siemens Foundation is now extending its funding for the “Miracle” project by CHF 12 million to a total of CHF 27 million.

Continue reading “Custom 3D-printed organic implants project funded with CHF 12 million”

3D Printing and the Corona virus

In the age of the Coronavirus many individuals, professionals and companies are looking into solutions in the fight against the Corona Virus / Covid-19 virus.

JakajimaTV hosted some interviews / presentations with three professionals with different backgrounds about their fight against Corona.

Watch the video’s below or subscribe to the JakajimaTV channel here.

Presentation by Alessandro Ricci, 3Dific


Presentation by Frans de Beer


Presentation by Frits Hoff, please not the special LinkedIn Group ‘local production of medical solutions fighting Corona / COVID-19′

Merck and EOS jointly develop powder based 3D Printer for printing tablets

tablets

Large-scale tablet production as we know it today was invented in the late 19th century. Although the machinery has, of course, become more modern, the manufacturing process has hardly changed and is still based on the compression of powders and granules.

This traditional tablet manufacturing process is very efficient for large-scale production. Yet, when active pharmaceutical ingredient (API) dosages need to be adapted – as it is the case for clinical studies or for any tablet batch production in smaller volumes – the process is both extremely time-consuming and expensive.

Merck together with EOS is currently developing a GMP-qualified solution that uses additive manufacturing (commonly known as 3D printing) technology combined with powder formulation. Laser sintering technology will simplify tablet production tremendously, leading to significant cost and time savings in clinical development.

PRODUCTION OF TABLETS HAS NEVER BEEN SIMPLER, FASTER AND CHEAPER

Tablet manufacturing using additive manufacturing will be as easy as “mixing, printing, done”. The API is mixed with excipients as a powder. A laser then fuses the mixture in a powder bed into tablets layer by layer. The tablets are then coated, and it’s all done!

In addition, 3D printing allows for API formulation to be scalable while avoiding costly reformulations throughout the entire pharmaceutical development and commercial production processes.  

This novel approach is being pursued at the Merck Innovation Center, which brings ideas, knowledge and people together to create new viable businesses beyond the company’s current scope. The innovation project can benefit greatly from the long-standing formulation expertise of our Healthcare business sector as well as the experience of our Life Science business with excipients. In addition, we are partnering with EOS, the world’s leading technology supplier in the field of industrial 3D printing of metals and polymers, on this project.

The goal is to establish, in a first step, a Contract Development and Manufacturing Organization offering tablet formulation development and production for clinical trials.

In addition to making tablet manufacturing simpler and reducing time and costs, we envision making it possible to mass produce tablets flexibly and sustainably in line with patient needs. Tablet production could be tailored locally to meet specific market requirements, for example. Or imagine how it could benefit children or elderly people by providing them with tablets in special shapes and colors so that they can easily recognize their medications.

The conference of 3D Medical Printing Conference covers the development of 3D Pharma Printing.

Read more about the Merck / EOS project on the website.

Translational Challenges in 3D-Bioprinting

By Prasad Shastri, Professor of Biofunctional Macromolecular Chemistry & Bioss Professor of Cell Signalling Environments / Director, Institute for Macromolecular Chemistry at University of Freiburg

3D-Bioprinting holds much promise in advancing medicine as tool to replicate cellular complexity of tissue environment ex vivo for drug screening and as a means of engineering well-defined functional tissue units for transplantation. In regards to the latter, 3D-bioprinting offers a critical link between principles of tissue engineering and patient-specific delivery of healthcare.

Continue reading “Translational Challenges in 3D-Bioprinting”

3D Point-of-Care: What, Why and How

materialise

duo presentation by

hospitalsSimon Vanooteghem, 3D Printing in Healthcare – Business Development, Materialise

maaike koenrades& Maaike Koenrades, Project Lead 3D Lab & Technical Physician, Medisch Spectrum Twente

Over the past 20 years, 3D Printing has emerged as a disruptive technology in the healthcare field — it’s been used to create custom devices and instruments, plan complex medical procedures, and to better train future medical professionals. As the accessibility to the technology increases, hospitals are beginning to adopt 3D printing programs within their own institutions, aiming to reduce lead times for 3D-printed models and to build knowledge internally.

Continue reading “3D Point-of-Care: What, Why and How”